Eisai's NDA for BANZEL Oral Suspension accepted for FDA review

Jul 19 2010

Eisai Inc. (Headquarters: Woodcliff Lake, NJ; President and CEO: Lonnel Coats), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's NDA for BANZEL^® (rufinamide) Oral Suspension (40 mg/mL). The proposed indication is for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older and adults. The application is based on data from a study designed to demonstrate the bioequivalence of the oral suspension formulation to the currently marketed BANZEL tablet formulation (400 mg).

Acceptance of the NDA indicates that the FDA has found the company's submission to be sufficiently complete to review. The NDA was submitted to FDA on April 30, 2010.

The BANZEL oral suspension was developed to provide a new option for children over four years and adults who have trouble swallowing tablets.

Source Eisai Co., Ltd.